Jim Birchenough
Stock Analyst at Wells Fargo
(2.35)
# 2,487
Out of 4,711 analysts
40
Total ratings
39.13%
Success rate
13.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGLS Regulus Therapeutics | Maintains: Equal-Weight | $2 → $3 | $1.59 | +88.68% | 5 | Mar 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $40.72 | +71.91% | 3 | Feb 22, 2024 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $1 | $2.47 | -59.51% | 1 | Nov 6, 2023 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $2.50 | +1,500.00% | 4 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $14.14 | +239.46% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.60 | +1,057.22% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.68 | +7,638.10% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $0.76 | +1,735.82% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $39.39 | +268.11% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $92.57 | -31.94% | 5 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $31.82 | - | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 | $16.98 | +229.80% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $701.85 | +4.58% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $6.38 | +2,721.32% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $5.63 | +486.15% | 3 | Jun 28, 2018 |
Regulus Therapeutics
Mar 13, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $1.59
Upside: +88.68%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $40.72
Upside: +71.91%
Sangamo Therapeutics
Nov 6, 2023
Downgrades: Equal-Weight
Price Target: $1
Current: $2.47
Upside: -59.51%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $2.50
Upside: +1,500.00%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $14.14
Upside: +239.46%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.60
Upside: +1,057.22%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.68
Upside: +7,638.10%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $0.76
Upside: +1,735.82%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $39.39
Upside: +268.11%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $92.57
Upside: -31.94%
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $31.82
Upside: -
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $16.98
Upside: +229.80%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $701.85
Upside: +4.58%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $6.38
Upside: +2,721.32%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $5.63
Upside: +486.15%